SCHRODER INVESTMENT MANAGEMENT GROUP
Position in JANX — Janux Therapeutics, Inc.
CIK 1086619
London, X0
Position in JANX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,712,723
-$972,580 QoQ
Shares Held
195,160
-26.9% QoQ
Ownership
0.320%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026SCHRODER INVESTMENT MANAGEMENT GROUP holds $603,082,920 across 77 Biotechnology names. JANX ranks #50 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
163,898 | $73,187,011 | |
| 2 | TECH |
BIO-TECHNE Corp
|
1,197,214 | $62,566,403 | |
| 3 | EXEL |
Exelixis, Inc.
|
525,533 | $22,540,109 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
66,662 | $22,056,454 | |
| 5 | SLNO |
Soleno Therapeutics Inc
|
648,827 | $21,722,727 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
39,852 | $20,861,326 | |
| 7 | INSM |
INSMED Inc
|
119,958 | $19,615,531 | |
| 8 | VERA |
Vera Therapeutics, Inc.
|
484,381 | $19,486,647 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,712,723 | 195,160 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $3,685,303 | 267,051 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $7,304,578 | 298,878 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $5,703,759 | 246,916 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $5,194,044 | 192,372 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $8,399,033 | 156,874 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $3,374,222 | 74,273 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $1,473,732 | 35,181 | Shares | Sole | 2024-08-12 | |
| No filing history on record for this holder in this stock. | ||||||